Crossmark

647 Phase I studies of AgenT-797, a novel allogeneic invariant natural killer T (iNKT) cell therapy, for the treatment of patients with solid tumors or multiple myeloma

Crossref DOI link: https://doi.org/10.1136/jitc-2022-SITC2022.0647

Published Online: 2022-11-07

Published Print: 2022-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Stevens, Don

Mo, Clifton

Garmezy, Benjamin

Hamm, John

Carneiro, Benedito

Wilky, Breelyn

Sanborn, Rachel

Khoueiry, Anthony El-

Buffa, Alexa

Munari, Sonia De

Yigit, Burcu

Purbhoo, Marco

Exley, Mark

Einstein, David
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct04754100 at ClinicalTrials.gov

Documents that mention this clinical trial

400 Persistence and tissue distribution of agent-797 – a native allogeneic iNKT cell-therapy drug product
https://doi.org/10.1136/jitc-2021-sitc2021.400

647 Phase I studies of AgenT-797, a novel allogeneic invariant natural killer T (iNKT) cell therapy, for the treatment of patients with solid tumors or multiple myeloma
https://doi.org/10.1136/jitc-2022-sitc2022.0647

nct05108623 at ClinicalTrials.gov

Documents that mention this clinical trial

1344 AgenT-797, an allogeneic iNKT cell therapy, demonstrates durable clinical activity in solid tumors: updated phase 1 findings
https://doi.org/10.1136/jitc-2025-sitc2025.1344

735 Peripheral and tissue persistence of agenT-797, an allogeneic iNKT cell-based cell therapy for the treatment of cancer
https://doi.org/10.1136/jitc-2023-sitc2023.0735

647 Phase I studies of AgenT-797, a novel allogeneic invariant natural killer T (iNKT) cell therapy, for the treatment of patients with solid tumors or multiple myeloma
https://doi.org/10.1136/jitc-2022-sitc2022.0647

nct05108623 at ClinicalTrials.gov

Documents that mention this clinical trial

1344 AgenT-797, an allogeneic iNKT cell therapy, demonstrates durable clinical activity in solid tumors: updated phase 1 findings
https://doi.org/10.1136/jitc-2025-sitc2025.1344

735 Peripheral and tissue persistence of agenT-797, an allogeneic iNKT cell-based cell therapy for the treatment of cancer
https://doi.org/10.1136/jitc-2023-sitc2023.0735

647 Phase I studies of AgenT-797, a novel allogeneic invariant natural killer T (iNKT) cell therapy, for the treatment of patients with solid tumors or multiple myeloma
https://doi.org/10.1136/jitc-2022-sitc2022.0647

Document is current

Any future updates will be listed below